Relay Therapeutics, Inc.

This early-stage study tests a new drug called RLY-8161 in people with advanced melanoma or other solid tumors that have a specific NRAS gene mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 35 participants will take the drug by mouth,…

This study tests a new drug, RLY-2608, in adults and children with rare conditions that cause abnormal overgrowth of body parts (like limbs or organs) due to a PIK3CA gene mutation. The drug targets only the mutated protein to try to reduce the size of overgrown tissue and improv…

This early-stage study tests a new drug, RLY-2608, designed to target a specific genetic mutation (PIK3CA) found in some advanced solid tumors and breast cancers. The trial will enroll about 930 adults whose cancer has not responded to other treatments. Researchers aim to find th…

This study tests whether a new drug, RLY-2608, combined with fulvestrant works better than another drug combo (capivasertib + fulvestrant) for people with a specific genetic mutation (PIK3CA) in advanced hormone-receptor-positive, HER2-negative breast cancer. About 540 adults who…